There are considerable differences in how patients respond to treatments due to a number of factors calling for personalised approaches to care, which is happening. However, the early promise of personalised medicine has not always translated into improved care for patients. Payers have concerns that current tests can be costly, requests for funding specific tests have subsequently been reversed as more information becomes available, and there is currently fragmentation in the funding of diagnostic tests. Payers also have concerns that pharmaceutical companies are exploiting the situation by seeking orphan status for their new targeted medicines driving up requested prices. It is also not clear who should fund biomarkers that accompany new expensive medicines. This is changing as the cost of tests come down, and payers develop new models to optimise the managed entry of new medicines as well as evaluate potential prices for new medicines for orphan diseases. There are also developments with ‘big data’ offering new understanding of disease complexity to enhance pipeline productivity and diagnosis as well as ongoing developments with drug resistance testing and research into the role of microbiomes to improve future health. Current challenges and concerns are being addressed. This will continue to improve patient care.
|Number of pages||5|
|Journal||Journal of Rare Diseases Research and Treatment|
|Publication status||Accepted/In press - 25 Nov 2016|
- patient response
- patient treatment
- drug resistance
Godman, B., Frost, I., Harrington, R., & Finlayson, AE. (Accepted/In press). Personalising medicine: feasibility and future implications from a payers' perspective. Journal of Rare Diseases Research and Treatment, 61-65.